Table 2.
All reported adverse events (AE) with their respective grades according to the CTCAE. Several AEs were possible in the same patient. Other * adverse events included: photosensitivity, pericardial effusion, arterial hypertension, loss of appetite, hyponatremia, hypercholesterinemia, acute kidney failure, alopecia, myalgia, sunburn, glomerulonephritis, erythema nodosum, neutropenia with erysipelas, sinusitis, hemophagocytic lymphohistiocytosis, elevated lipase and alcalic phosphatase, pancreatitis, hypophosphatemia, dyspnea, lymphopenia, and ageusia.
| Adverse Event (AE) | First BRAFi+MEKi Combination | Second BRAFi+MEKi Combination | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| V+C (n = 23) | D+T (n = 65) | E+B (n = 6) | V+C (n = 31) | D+T (n = 24) | E+B (n = 39) | |||||||||||||||||||||||||||||||
| Grade 1 | Grade 2 | Grade 3 | Grade 1 | Grade 2 | Grade 3 | Grade 1 | Grade 2 | Grade 3 | Grade 1 | Grade 2 | Grade 3 | Grade 1 | Grade 2 | Grade 3 | Grade 1 | Grade 2 | Grade 3 | |||||||||||||||||||
| n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
| Highest grade AE | 4 | 17 | 6 | 26 | 7 | 30 | 9 | 14 | 17 | 26 | 23 | 35 | 4 | 67 | 1 | 17 | 1 | 17 | 6 | 19 | 9 | 29 | 11 | 36 | 5 | 21 | 7 | 30 | 6 | 25 | 5 | 13 | 6 | 15 | 13 | 33 |
| Pyrexia | 3 | 13 | 1 | 4 | 1 | 4 | 10 | 15 | 13 | 20 | 6 | 9 | 0 | 0 | 1 | 17 | 0 | 0 | 3 | 10 | 2 | 6 | 1 | 3 | 2 | 8 | 5 | 21 | 3 | 13 | 0 | 0 | 2 | 5 | 1 | 3 |
| Rash | 2 | 9 | 1 | 4 | 6 | 26 | 6 | 9 | 2 | 3 | 3 | 5 | 2 | 33 | 0 | 0 | 0 | 0 | 5 | 16 | 3 | 10 | 8 | 26 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 8 | 0 | 0 | 1 | 3 |
| Fatigue | 1 | 4 | 1 | 4 | 0 | 0 | 8 | 12 | 3 | 5 | 3 | 5 | 1 | 17 | 0 | 0 | 0 | 0 | 2 | 6 | 1 | 3 | 0 | 0 | 2 | 8 | 1 | 4 | 0 | 0 | 4 | 10 | 1 | 3 | 0 | 0 |
| Gastrointestinal | 1 | 4 | 2 | 9 | 0 | 0 | 10 | 15 | 3 | 5 | 5 | 8 | 5 | 83 | 0 | 0 | 0 | 0 | 3 | 10 | 3 | 10 | 1 | 3 | 1 | 4 | 3 | 13 | 0 | 0 | 1 | 3 | 2 | 5 | 4 | 10 |
| Elevated liver enzymes | 2 | 9 | 0 | 0 | 1 | 4 | 0 | 0 | 2 | 3 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 0 | 0 | 1 | 4 | 0 | 0 | 1 | 3 | 3 | 8 |
| Panniculitis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cardiac toxicity | 0 | 0 | 2 | 9 | 0 | 0 | 0 | 0 | 2 | 3 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Elevated creatine kinase | 0 | 0 | 1 | 4 | 1 | 4 | 4 | 6 | 2 | 3 | 2 | 3 | 1 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 |
| Arthralgia | 1 | 4 | 0 | 0 | 1 | 4 | 7 | 11 | 5 | 8 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 10 | 1 | 3 | 1 | 4 | 1 | 4 | 1 | 4 | 0 | 0 | 2 | 5 | 1 | 3 |
| Pulmonal toxicity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ocular toxicity | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 8 |
| Peripheral edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Thrombopenia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other * | 2 | 9 | 3 | 13 | 6 | 26 | 8 | 12 | 3 | 5 | 2 | 3 | 1 | 17 | 0 | 0 | 1 | 17 | 3 | 10 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 2 | 8 | 2 | 5 | 3 | 8 | 3 | 8 |